Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock Has Consensus Price Target of $95.00

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $95.00.

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Needham & Company LLC increased their target price on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. BTIG Research decreased their target price on shares of Establishment Labs from $103.00 to $93.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Finally, Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a research report on Thursday, August 6th.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $68.62 on Tuesday. The company has a debt-to-equity ratio of 17.17, a current ratio of 3.57 and a quick ratio of 2.52. Establishment Labs has a 1-year low of $53.16 and a 1-year high of $97.59. The stock’s 50-day moving average is $66.07 and its 200 day moving average is $72.34.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Friday, October 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 196.38% and a negative net margin of 14.56%. The firm had revenue of $71.99 million during the quarter, compared to analysts’ expectations of $66.81 million. During the same period in the prior year, the company earned ($0.38) EPS. The firm’s quarterly revenue was up 33.8% compared to the same quarter last year. On average, equities research analysts expect that Establishment Labs will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. First Trust Advisors LP increased its stake in shares of Establishment Labs by 41.4% in the third quarter. First Trust Advisors LP now owns 140,030 shares of the company’s stock worth $8,986,000 after buying an additional 41,026 shares during the period. Public Sector Pension Investment Board bought a new stake in Establishment Labs during the 3rd quarter valued at $2,372,000. Global Retirement Partners LLC boosted its position in Establishment Labs by 23,400.0% during the 3rd quarter. Global Retirement Partners LLC now owns 2,350 shares of the company’s stock valued at $151,000 after buying an additional 2,340 shares during the period. CenterBook Partners LP boosted its position in Establishment Labs by 123.9% during the 3rd quarter. CenterBook Partners LP now owns 9,033 shares of the company’s stock valued at $580,000 after buying an additional 4,999 shares during the period. Finally, State of Wyoming boosted its position in Establishment Labs by 102.1% during the 3rd quarter. State of Wyoming now owns 2,057 shares of the company’s stock valued at $132,000 after buying an additional 1,039 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.